Zoetis Inc. logo
Zoetis Inc. (ZTS)
Compare

Zoetis Inc. (ZTS) Average EV/EBITDA Ratio

EV/EBITDA Ratio

The current ev/ebitda ratio for Zoetis Inc. (ZTS) is 10.35x as of Thursday, June 11, 2026, shown against its trailing averages.

Average EV/EBITDA Ratio Chart

ZTS EV/EBITDA Ratio Averages

EV/EBITDA RATIO CURRENT

10.35x

EV/EBITDA RATIO TTM

15.64x

EV/EBITDA RATIO 3Y

20.67x

EV/EBITDA RATIO 5Y

23.75x

EV/EBITDA RATIO 10Y

24.25x

EV/EBITDA RATIO 15Y

23.37x

EV/EBITDA RATIO 20Y

23.37x

About Zoetis Inc.

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Parsippany, NJ
13,800 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Kristin C. Peck